Cover Image
市場調查報告書

PharmaSphere:南美的醫藥品、醫療產業的資本交易趨勢

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

出版商 GlobalData 商品編碼 295032
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
PharmaSphere:南美的醫藥品、醫療產業的資本交易趨勢 PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
出版日期: 2014年01月31日 內容資訊: 英文 103 Pages
簡介

本報告提供南美各國的製藥、醫療產業的近幾年的資本交易趨勢相關分析、地區整體交易數量、金額趨勢、及全球整體趨勢與的相異點、各國市場及各交易型態的詳細趨勢、近幾年的代表性交易的案例、交易的促進與阻礙因素、政策、宏觀經濟等的影響、今後的市場方向性等調查資料、考察,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 過去的資本交易趨勢

  • 概要
  • 資本交易主要的推動因素
    • 全球醫藥品市場低迷
    • 知識產權(IP)相關的問題和競爭加劇
    • 國民全部保險制度(通用醫療利用)、基礎醫療、健康保險
    • 企業整合的發展
  • 資本交易的整體趨勢
    • 各種類的趨勢分析

第4章 各國市場概況

  • 巴西
    • 概要
    • 大型資本交易的數量與交易額
    • 市場動態
  • 墨西哥
  • 阿根廷
  • 委內瑞拉

第5章 企業合併、收購(M&A)

  • 概要
  • 案例研究(共5件)

第6章 許可證交付契約

  • 概要
  • 案例研究(共5件)

第7章 產業聯盟、夥伴關係

  • 概要
  • 案例研究(共5件)

第8章 主要企業的資本交易策略

  • Amil Participacoes S.A.
    • 近幾年的資本交易趨勢(M&A、許可證、夥伴關係)
    • 整體資本交易策略
  • Hypermarcas
  • Grupo Casa Saba
  • Genomma Lab Internacional
  • CFR Pharmaceuticals

第9章 未來展望

  • 概要
  • 交易趨勢預測
    • 企業合併、收購(M&A)
    • 許可證/夥伴關係:擴充產品結構和促使開發中產品成長的交易數量增加
    • 進入市場的課題伴隨的對資本交易發動的影響

第10章 附錄

圖表一覽

目錄
Product Code: GDHC009PSR

"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.

The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.

Highlights

Key Questions Answered

  • How are the main deal categories faring among top countries in the Latin America region over the past five years?
  • What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
  • What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
  • What strategies are the most successful companies pursuing to gain and maintain their market leading position?
  • Which are the key companies that are potential targets of acquisitions?

Scope

  • Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
  • Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
  • Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
  • Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
  • Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
  • Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
  • Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.

Reasons to buy

  • Understand the primary drivers behind major deal initiatives in the LATAM region.
  • Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
  • Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
  • Use this information as an independent source for your due diligence and transaction strategy.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
    • 2.1.1. Key Questions Answered
    • 2.1.2. Key Benefits
    • 2.1.3. Upcoming Related Reports

3. Historical Dealmaking Trends

  • 3.1. Overview
  • 3.2. Leading Deal Drivers
    • 3.2.1. Dampening Global Pharmaceutical Markets
    • 3.2.2. Intellectual Property Issues and Rising Competition
    • 3.2.3. Universal Healthcare Access, Primary Healthcare, and Health Insurance
    • 3.2.4. Increasing Consolidation
  • 3.3. Overall Deals in Review
    • 3.3.1. Review by Deal Type

4. Regional Country Profiles

  • 4.1. Brazil
    • 4.1.1. Overview
    • 4.1.2. Top Deals by Value and Volume
    • 4.1.3. Market Dynamics
  • 4.2. Mexico
    • 4.2.1. Overview
    • 4.2.2. Top Deals by Value and Volume
    • 4.2.3. Market Dynamics
  • 4.3. Argentina
    • 4.3.1. Overview
    • 4.3.2. Top Deals by Value and Volume
    • 4.3.3. Market Dynamics
  • 4.4. Venezuela
    • 4.4.1. Overview
    • 4.4.2. Top Deals by Value and Volume
    • 4.4.3. Market Dynamics

5. Mergers and Acquisitions

  • 5.1. Overview
  • 5.2. Case Studies
    • 5.2.1. UnitedHealth Group Acquires Amil Participacoes
    • 5.2.2. Hypermarcas Acquires Mantecorp Industria Quimica e Farmaceutica
    • 5.2.3. Hypermarcas Acquires Laboratorio Neo Quimica
    • 5.2.4. Acquisition of Lafrancol (Colombia) by Recalcine (Chile)
    • 5.2.5. Sanofi Aventis Acquires Medley Industria Farmaceutica

6. Licensing Agreements

  • 6.1. Overview
  • 6.2. Case Studies
    • 6.2.1. FBM Industria Farmaceutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals
    • 6.2.2. FAES Farma and Pfizer Expand Bilastine License Agreement
    • 6.2.3. CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm
    • 6.2.4. Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma
    • 6.2.5. Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratorios

7. Collaborations and Partnerships

  • 7.1. Overview
  • 7.2. Case Studies
    • 7.2.1. Pfizer Enters into an Agreement with Laboratorio Teuto Brasileiro
    • 7.2.2. Avesthagen Forms a Joint Venture with Uxmal
    • 7.2.3. Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment
    • 7.2.4. Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines
    • 7.2.5. Ache , Uniao Quimica Farmaceutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture

8. Deal Strategy of Major LATAM Companies

  • 8.1. Amil Participacoes S.A.
    • 8.1.1. Recent Deals: M&As, Licensing, and Partnerships
    • 8.1.2. Overall Deal Strategy
  • 8.2. Hypermarcas
    • 8.2.1. Recent Deals: M&As, Licensing, and Partnerships
    • 8.2.2. Overall Deals Strategy
  • 8.3. Grupo Casa Saba
    • 8.3.1. Recent Deals: M&As, Licensing, and Partnerships
    • 8.3.2. Overall Deals Strategy
  • 8.4. Genomma Lab Internacional
    • 8.4.1. Recent Deals: M&As, Licensing, and Partnerships
    • 8.4.2. Overall Deals Strategy
  • 8.5. CFR Pharmaceuticals
    • 8.5.1. Recent Deals: M&As, Licensing, and Partnerships
    • 8.5.2. Overall Deals Strategy

9. Future Outlook

  • 9.1. Overview
  • 9.2. Deal-Making Trends
    • 9.2.1. Mergers and Acquisitions
    • 9.2.2. Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth
    • 9.2.3. Market Access Challenges will Impact Deal Activity

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. About the Author
    • 10.3.1. Industry Analyst
  • 10.4. Director of Healthcare Industry Dynamics
  • 10.5. Global Head of Healthcare
  • 10.6. About the Industry Dynamics Team
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012
  • Table 2: Market Share Split of Pharma Firms in Brazil
  • Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012
  • Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020
  • Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise
  • Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise
  • Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012
  • Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020
  • Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise
  • Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012
  • Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020
  • Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012
  • Table 13: UnitedHealth Acquires Amil Participacoes
  • Table 14: Hypermarcas Acquires Mantecorp
  • Table 15: Hypermarcas Acquires Laboratorio Neo Quimica Comercio e Industria
  • Table 16: Recalcine Acquires Lafrancol
  • Table 17: Sanofi Aventis Acquires Medley Industria Farmaceutica
  • Table 18: Major Licensing Deals, LATAM Region, 2008-2012
  • Table 19: FBM Farma Industria Farmaceutica Licenses Zertane from Ampio Pharmaceuticals
  • Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine
  • Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm
  • Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma
  • Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratorios
  • Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012
  • Table 25: Pfizer Enters Into An Agreement With Laboratorio Teuto Brasileiro
  • Table 26: Avesthagen Enters into Agreement with Uxmal
  • Table 27: Baxter International Enters Into Agreement With Hemobras
  • Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture
  • Table 29: Ache , Uniao Quimica Farmaceutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture
  • Table 30: Amil Participacoes ' Recent Deals Activity
  • Table 31: Hypermarcas' Recent Deals Activity
  • Table 32: Grupo Casa Saba's Recent Deals Activity
  • Table 33: Genomma Lab Internacional's Recent Deals Activity
  • Table 34: CFR Pharmaceuticals' Recent Deals Activity

List of Figures

  • Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012
  • Figure 2: Research and Development Spending of PhRMA Members, 2005-2012
  • Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012
  • Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012
  • Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012
  • Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012
  • Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012
  • Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012
  • Figure 9: Trends in Deal Volume in Brazil, 2008-2012
  • Figure 10: Volume of Deal Types in Brazil, 2008-2012
  • Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020
  • Figure 12: Trends in Deal Volume in Mexico, 2008-2012
  • Figure 13: Volume of Deal Types in Mexico, 2008-2012
  • Figure 14: Trend in Market Forecast in Mexico, 2011-2020
  • Figure 15: Trends in Deal Volume in Argentina, 2008-2012
  • Figure 16: Volume of Deal Types in Argentina, 2008-2012
  • Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020
  • Figure 18: Trends in Deal Volume in Venezuela, 2009-2012
  • Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012
  • Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020
  • Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012
  • Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012
Back to Top